# 

cagcagccag

gtttcaatga

gggttcagca

tgaagactat


atgattacca

atggcagagc

Novel Antibodies and Ligands...

Ù,

Inventors: Michael J. Briskin et al.



gtacctggtg cctggtgttt tggccaggtc gctcatcctc ctacaaccag gatatccctg actgggggttc ggctgtgttc ctgggaatac atacctgagg gaacttctgg cagcatgttc cttctaccat gctcatatgt actgcttcat gcagcacaca aggccatcgc tggaggccac tgccctgcat tcatatccat ccctggctga aatgggtgtt taatcaaaac tctcacatca acacgtccat ccaccaagge tcatctgggt atctcgacaa cccagatgac tcctggtgat agtttcgaaa aaggtctttc ctggtgctgg gtgaacctac ggcatccatg gtggttaagg accagettge aatgtcttta gttcttgcca tattcagtca aagatcatct aagttcatcc atggtgacag gtcagcctga tacctigggg tcccacaatg attaacttct gattgtctgc tttttctgcc ttgcctccct tttcattgta gggcaaggtc tatctatggc ttccactgtg caacctcatg ctacaccatc ctatgccttt gcagttcagc ggggaactct tgtgttcctg ggcctatgca catctacact cagatitita gcctgacgga gcctactggg ggatgacctg acgaggcaat tccagaagca agatgccctt ccagctttca aggacattgg attccaagac aagacttcct gtggtctggt tgaaattatg ctgtggatcg tgccccaaat tgataacat accetgtget gctggaggct ctgctgaccc aaacttgtga gtctgcactc acctgcatca caagccaaga ttcttgccac tatgccatga tctgaggaca aagttgcaga atgtgcaaga ctggtttcct ggttaccatg gcctgcctta gaggagcatc gtgtttgtct cagttatag

961

781

ز

61

181

301

361

421

481

541

601

661

721

MAEHDYHEDY GFSSFNDSSQ EEHQDFLQFS KVFLPCMYLV VFVCGLVGNS LVLVISIFYH KLQSLTDVFL INFYTSMLIL TCITVDRFIV VVKATKAYNQ GYHDEAISTV VLATQMTLGF FLPLLTMIVC KIIFLVMAVF LLTQMPFNLM KFIRSTHWEY YAMTSFHYTI MVTEAIAYLR δľ SEDNSKTFSA SHNVEATSMF GIHEWVFGQV MCKSLLGIYT ACLNPVLYAF VSLKFRKNFW KLVKDIGCLP YLGVSHQWKS NVFNLDKLIC QAKRMTWGKV TSLLIWVISL LVSLPQIIYG YSVIIKTLLH AGGFOKHRSL VCTLPFWAYA VNLPLADLVF

1040

## 世 (で)

260 390 520 650 910 780 GGAGGCAACAAGGACCCATGGGTTCAGGAATTGATGAGGCTGTCTTGATCTCAAAGAATGTGGACATGCTTACTCGGGGATTGTGGGCCCACCAGAGCATTACT1<mark>c</mark>ctaccagcccccaatttctcagg CCTCAGAGGGGGCATCÌTCAGATATCCACACCCCTGCCCAGATGCTCCTGTGCACTTGCAGTCCACTCAGCGCCCCTCCCAGTAGGATCACTGTCCTCGGACAAAGAGCTCACTCGTCCCAAATGA 
 AACCACCATTCACACTGCGGGCCACAGATTGGGCCTGAGGCTGGGGAGAACCAGAAGCAGCCGGAAAAAAATGCTGGTCCCACAGCCACAGACATCAGCCACAGTGCCGGTCCTGTGCCTCCTG
 CCAAGAATGGAAGCTTGTGAGGAGACGGACTCTATGTJGCCGGGCTGTTATGGAACTCCTGAGTCAAGTGCATCCTCCCACCTTGGCCTCTGAAGGTGCGAGGATTATAGGCGTCACCTACACATCCAG ITGTGGTAAAAGAATTICTTCCGACTCCGCCATCGGTTCAGATCGTCTCCGGAAACACCTGAGAGCTTACCATCGGTGTTCTATACTACACGAGGTTCCAGCTCCTTTCCTGGAGCGTGT တ w I œ <u>.</u>

GCCICCICCTGAGTAGCTGGGACIACAGGTGCTCACCACACCCGGCTAATTTTTGTATTTTTAGTAGAGCCGGGGTTTCACCATGTTGACCAGGCTGGTCTCGAACTCCTGACCTGGTGATCTGC 1300 CCACCCAGGCCTCCCAAAGIGCTGGGATTAAAGGIGIGAGCCACCATGCCTGTGTGTGTGTTTTTTAACTACTAAAAATTATTTTGTAATGATTGAGTCTTCTTTATGGAAACAACTGGCCTCAG 1430 

ATGIGIATITIGITITGITITGCTTTGCTTTGTTTTGAGACGGABTCTCGCTCTGTCATCCAGGCTGGAGTGCATGATCTCGGCTCACTGCAACCCCCATCTCCCAGGTTCAAGCGATTCTCCT 1170

CCTACACGTATTIGTTAATATCTAACATAGGACTAACCAGCCACTGCCCTCTTAGGCCCCTCATTTAAAAACGGTTATACTATAAAATCTGCTTTTCACACTGGGTGATAATAACTTGGACAAATTCT

### FIG. 4A

1.	•		
CGGCGACTCTCTCCACCGGGCCGCCCGGGAGGCTCATGCAGCGCGGCTGG	GTC	CGCG	GC
61			
GCCCGGATCGGGGAGGTGAAAGTGCCTCGGAGGAGGAGGGCCGGTCCGGC	AGTO	CAGC	CG
121			
	•		
CCTCACAGGTCGGCGGACGGGCCAGGCGGGCGGCCTCCTGAACCGAACCG	AATC	GGCT	cc
181			
			,
TCGGGCCGTCGTCCTCCCGCCCCTCCTCGCCCGCCGCGAGTTTTCTTT	CGGT	ռեժեն	rc
241			
CAAGATTCCTGGCCTTCCCTCGACGGAGCCGGGCCCAGTGCGGGGGGCGCA	GCGC	cccc	2.20
301	<b>-</b>	50000	<i>7</i> .
GCTCCACCTCCTCGGCTTCCCTGCGTCCAGAGGCTGGCATGGCGCGGGC	~~~~~	ma cime	• •
361	JUAG	TACTO	1 <i>P</i> 3.
201			
	Samaiı		
GCGCACGGTCGGGGCACAGCAGGGCCGGTGGGTGCAGCTGGCTCGCGCCTC	_C1C.	الالالالغا	ıC.
421			
	, 2020		~
CGCCGTCTCCGGTCCCCGGCGAAAGCCATTGAGACACCAGCTGGACGT	CACC	3CGCC	G
481			
			_
GAGCATGTCTGGGAGTCAGAGCGAGGTGGCTCCATCCCCGCAGAGTCCGCG	GAGC	cccc.	A
541			
GATGGGACGGGACTTGCGGCCCGGGTCCCGCGTGCTCCTGCTTCT			
MGRDLRPGSRVLLLLL	_L	I, I	20
601			
GGTGTACCTGACTCAGCCAGGCAATGGCAACGAGGGCAGCGTCACTGGAAG	TTGT	TATTO	3
<u>V Y L T O P G</u> N G N E G S V T G S	C Y	C	40
661			•
TGGTAAAAGAATTTCTTCCGACTCCCCGCCATCGGTTCAGTTCATGAATCG	TOTO	CGGAA	
G K R I S S D S P P S V Q F M N R			
G K K I S S D S I I S V Q I M M K	. س		00
721			
/ <del>/ /                                  </del>			
	mmoon	<b></b>	
ACACCTGAGAGCTTACCATCGGTGTCTATACTACACGAGGTTCCAGCTCCT	-		
HLRAYHRCLYYTRFQLL	S	w s	80
781			
CGTGTGTGGAGGCAACAAGGACCCATGGGTTCAGGAATTGATGAGCTGTCT			
V C G G N K D P W V O E L M S C L	D :	L K	100

### FIG. 4B

8	41				•	•															
	AC:	יים ב'	arra (	בארו	י שרבים	د بلادفات	י שיי		י מיביב	יבויות	rac	~~ <u>~</u>	a c c :	מבים ב	אכר	אלאט ע	יים מיזי		יא מחי	CAG	
	E	C	G		A		S			V					H	-		P	T	S	120
9	01																				
			ממר	ابلغلام	ا جاللند	יככנ	ئىلەماد	אכז	י כיכינ מי	2001	ייטימי	المعلات	נממי	ימידים	ויריריז	אראנ		اتاراتار		GAT	
		P		S	0	A.G.C.	.cr s	_AGr E	G	A		S	D	I	H	r T	P	A	م 0	M	140
					_														~		
9	61																				
												. ~	.~~								
	GC.			CAC T		rGCF O	AGT'( S	CAC T	TTC! O	AGCC R		CAC T	CC1 L	rccc P	:AG1 V	'AGC G	STAE S	ACT L	rgtc S	CTC	1.00
	11	נו	3	1		V		1	~	Д	F	_	יב	Γ.			٥	1.1	5	S	160
10	21																				
				•				•												•	
						TCG															
	D	K	E	L	T	R	P	N	E	T	T	I	H	T	A	G	H	S	L	A	180
108	1																				
	AGT	TGG	GCC	TGA		TGG			CCA	GAA	.GCA	GCC	GGA	AAA	AAA	TGC	TGG	TCC	CAC	AGC	
	V	G	. Р	Ė	A	G,	E	N	Q	K	Q	P	E	K	N	A	G	P	T	A	200
11	47						•														
	CAG	GAC	ATC	AGC	CAC	AGT	GCC	GGT	CCT	GTG	CCT	CÇT	GGC	CAT	CAT	TTT(	CAT	CT	CAC	CGC	
	$\mathbf{R}$	T	S	A	T	V	P	v	Ļ	С	L	L	A	I	I	F	I	L	T	A	220
120	01																				
	AGC	CCT	יזייי	CTA	TGT	GCT	GTG	CAA	GAG	GAG	GAG	GGG	GCA	GTC	ACC	3CA	GTC	ישיבי	rcca	GA	
		L		Y	v	Ŀ	C		R			G			P	Q		S	P	D	240
																	•				
126	51																				
					<b></b>	~~~			~~~				ma -a c		· ·					- ~	
	TCI L	GCC P		TCA H		TAT. I				ACC P		CTC: S	raa. N		- 1 GA	AGC C	AAC	AA'I	A ف	AG	254
	u		٧	11	1	1	F	٧	A	F	ט	٠.	14	•							234
132	21																				
				•							•			•			.•				
10		GTG	AGG	AGA	.CGG	ACT	CTA	TGT	TGC	CCA	GGC'	TGT'	ratc	3GA2	ACTO	CTC	SAGI	'CAA	GTG	ĄΥ	
138	ВŢ																		•	*	
	CCI	יככר יככר	ACC	TTG	GCC	TCT	GAA	.GGT	GCG	AGG:	· ATT	ATA(	GGC0	GTC	ACC1	ACC	ACA	TCC	AGC	CT	
14																					
	-	•		•	•									•							
	ACA	CGT	TTA	TGI	'T'AA	TAT	CTA	ACA	TAG	GAC	TAA	CCA	GCC2	ACTO	SCCC	TCT	CTI	AGC	CCC	CT	

### FIG. 4C


150	
15	CATTTAAAAACGGTTATACTATAAAATCTGCTTTTCACACTGGGTGATAATAACTTGGAC
16	AAATTCTATGTGTATTTTGTTTTGTTTTGCTTTGCTTTTGTTTTGAGACGGAGTCTCGCTC
16	TGTCATCCAGGCTGGAGTGCAGTGGCATCTCCCAG
17	. GTTCAAGCGATTCTCCTGCCTCCTAAGTAGCTGGGACTACAGGTGCTCACCACCACA 41
18	CCCGGCTAATTTTTTGTATTTTAGTAGAGACGGGTTTCACCATGTTGACCAGGCTGGT 01
. 18	CTCGAACTCCTGACCTGGTGATCTGCCCACCCAGGCCTCCCAAAGTGCTGGGATTAAAGG 61
19:	. TGTGAGCCACCATGCCTGGCCCTATGTGTGTTTTTTTTAACTACTAAAAATTATTTTTGTAA 21
	TGATTGAGTCTTCTTTATGGAAACAACTGGCCTCAGCCCTTGCGCCCTTACTGTGATTCC
19	981
204	TGGCTTCATTTTTTGCTGATGGTTCCCCCTCGTCCCAAATCTCTCTC
210	TGTTCCTCCCCACCTCAGCCCTCTCCTGCATCCTCCTGTACCCGCAACGAAGGCCTGGG
21	CTTTCCCACCCTCCTTAGCAGGTGCCGTGCTGGGACACCATACGGGTTGGTT
222	CTCCTCAGTCCCTTGCCTACCCCAGTGAGAGTCTGATCTTGTTTTTTTT
221	
	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,


tgttcctggg aagatgggga cgctgaagaa ttaagaaact cttatgattt tcaccagcct cgcctcacgc cccgggctgc ttgtgttatc gaagctgaag cccaggcaca ctgatagcca aagaaaataa gctatatagc cttctgatat cactgcccaa cccgctgtac gtgtgcattt ccaggtccgt cgccagcgct ccgggttctg acctgcaagc agaccacctc ctgcctacgt gtgaaagaaa tggtcgcctt cccactgccc tagctactag agctccgcag ctgccacttg aaggccggac caatctaact ctgtgtgtga aaataaatc ggaggtgatc tggaaggaaa taaataaaca ccgcagcatg cctgcagtgc tttccagttt gttgctgctc tttggagagt 421 181 241 301 361


MSSAAGFCAS RPGLLFLGLL LLPLVVAFAS AEAEEDGDLQ CLCVKTTSQV RPRHITSLEV IKAGPHCPTA


വ QLIATLKNGR KICLDLQAPL YKKIIKKLLE

2500 | The state of the state o












FIG. 9E




FIG. 9F






FIG. 9G








FIG. 11B





FIG. 11C






FIG. 11G









FIG. 11H





























FIG. 17A

CD3 Blasts




FIG. 17B

LAK Cells








FIG. 18










60 40 40 40 3 6 9 9 9 11.2 Days

% Bonzo-positive Cells






FIG. 24A




FIG. 24B




FIG. 24C




FIG. 24D




FIG. 24E




FIG. 24F




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D




FIG. 25E




FIG. 25F




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 26D




FIG. 26E




FIG. 26F





FIG. 27




 $\Box$ TR1


⊠T<sub>H</sub>2

⊠T<sub>H</sub>1

FIG. 28









Soluble SExCkine Potential Cleavage Sites Membrane bound SExCkine Cytoplasmic Tail Mucin Stalk Transmembrane region N-terminal Chemokine Domain \_\_\_\_\_

FIG. 30

+ 7A2 -- IgG2a -- 9G2 -- IgM




FIG. 32

